Merus (MRUS)
(Delayed Data from NSDQ)
$50.99 USD
+0.51 (1.01%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $50.55 -0.44 (-0.86%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MRUS 50.99 +0.51(1.01%)
Will MRUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRUS
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for MRUS
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine?s RNA Platform
Merus, Foundation Medicine collaborate to advance treatments for NRG1+
Buy Rating on Merus Backed by Strong Clinical Advantages and Market Positioning
Franklin Biotechnology Discovery Fund Q2 2024 Commentary
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks